Millipore has taken its high capacity chromatography media a step further by eliminating the use of mammalian derived materials
The demand for therapeutical monoclonal antibodies has increased, necessitating high-throughput capability at initial capture.
In the meanwhile, regulatory authorities have directed the biopharmaceutical industries to eliminate mammalian derived materials from their processes.
Therefore, Millipore has developed Prosep-vA high capacity media to fulfill both these requirements.
New Prosep-vA is equivalent to its predecessor, Prosep-A high capacity media in both functionality and specification.
Both are made with natural protein A derived from Staphylococcus aureus.
However, by eliminating the use of mammalian materials from the manufacturing process for protein A, Millipore reduces the potential risks of contamination to personnel through contact with such materials.
The highly porous glass matrix has a large percentage of open ended, interconnected pores allowing high flow rates at relatively low back pressures. The resulting high dynamic capacity maximises productivity and can reduce the need for a concentration step prior to loading. Prosep-vA also provides greater flexibility in column selection and process design optimisation.
Prosep-vA is ideally suited for the capture step in the purification of monoclonal, polyclonal and engineered antibodies.
Eight-pack sizes are available ranging from 2ml to 10l.
Further to the advantages of improved process time, enhanced productivity and reduced costs, Millipore's animal free high capacity media also reduces the potential risks of using mammalian derived material.
Prosep-vA high capacity media with animal free protein A replaces Prosep-A high capacity media, which will be available to existing users until July 2004.
